Ginkgo Bioworks (US:DNA) ZACKSยท2025-10-22 23:15Core Viewpoint - Ginkgo Bioworks Holdings, Inc. is experiencing a decline in stock price and is expected to report significant losses in its upcoming financial results, indicating potential challenges ahead for the company [1][2]. Financial Performance - The company closed at $12.78, reflecting a -2.67% change from the previous day, which is worse than the S&P 500's loss of 0.53% [1]. - Anticipated EPS for the upcoming release is -$1.24, a decrease of 14.81% compared to the same quarter last year [2]. - Projected revenue for the upcoming quarter is $39 million, down 56.2% from the year-ago period [2]. - For the full year, the consensus estimates project an EPS of -$5.27 and revenue of $181 million, showing changes of +49.13% and -20.28% respectively from the previous year [3]. Analyst Estimates - Recent adjustments to analyst estimates for Ginkgo Bioworks may reflect changing business dynamics, with positive revisions indicating analyst optimism [4]. - The Zacks Rank system, which assesses these estimate changes, currently ranks Ginkgo Bioworks at 3 (Hold), with no changes in EPS projections over the past 30 days [6]. Industry Context - Ginkgo Bioworks operates within the Medical - Biomedical and Genetics industry, which has a Zacks Industry Rank of 92, placing it in the top 38% of over 250 industries [7]. - The top 50% rated industries are shown to outperform the bottom half by a factor of 2 to 1, indicating a competitive environment for the company [7].